Details for New Drug Application (NDA): 021145
✉ Email this page to a colleague
The generic ingredient in VANIQA is eflornithine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eflornithine hydrochloride profile page.
Summary for 021145
Tradename: | VANIQA |
Applicant: | Skinmedica |
Ingredient: | eflornithine hydrochloride |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021145
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CREAM;TOPICAL | Strength | 13.9% | ||||
Approval Date: | Jul 27, 2000 | TE: | RLD: | Yes |
Expired US Patents for NDA 021145
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Skinmedica | VANIQA | eflornithine hydrochloride | CREAM;TOPICAL | 021145-001 | Jul 27, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Skinmedica | VANIQA | eflornithine hydrochloride | CREAM;TOPICAL | 021145-001 | Jul 27, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Skinmedica | VANIQA | eflornithine hydrochloride | CREAM;TOPICAL | 021145-001 | Jul 27, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription